EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT
Mark Monane, David Merrill, Kim Johnson, Darren Gitelman, Demetrius Maraganore, Leslie Jacobs, Yan Jiang, Joel Braunstein · 2024
Read EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT by Mark Monane, David Merrill, Kim Johnson, Darren Gitelman, Demetrius Maraganore, Leslie Jacobs, Yan Jiang, Joel Braunstein (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11692392.txt.
Description
Mark Monane and co-authors report early results on how doctors use a blood test for Alzheimer's disease in real clinics, in this 2024 paper. Timely diagnosis of memory problems needs tools that are simple and light on patients. The test joins two blood measures, covering amyloid and a tau marker, into one score. That score estimates the chance that brain amyloid, the disease's hallmark, will show on a scan. Earlier work found it caught most true cases.
The study behind the report tracks how the test changes real care choices for people with cognitive complaints. Early utility data can show whether the score shifts diagnosis, referrals, or treatment plans. A blood test that doctors trust and act on could spare many patients costly scans and long waits.
Catalog record
| CREATOR | Mark Monane, David Merrill, Kim Johnson, Darren Gitelman, Demetrius Maraganore, Leslie Jacobs, Yan Jiang, Joel Braunstein |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |